CN1500509A - A kind of traditional Chinese medicine composition for treating depression and anxiety - Google Patents
A kind of traditional Chinese medicine composition for treating depression and anxiety Download PDFInfo
- Publication number
- CN1500509A CN1500509A CNA021486204A CN02148620A CN1500509A CN 1500509 A CN1500509 A CN 1500509A CN A021486204 A CNA021486204 A CN A021486204A CN 02148620 A CN02148620 A CN 02148620A CN 1500509 A CN1500509 A CN 1500509A
- Authority
- CN
- China
- Prior art keywords
- heart
- chinese medicine
- depression
- anxiety
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 208000019901 Anxiety disease Diseases 0.000 title claims description 9
- 230000036506 anxiety Effects 0.000 title claims description 8
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 206010002869 Anxiety symptoms Diseases 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 230000000994 depressogenic effect Effects 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 206010054089 Depressive symptom Diseases 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- -1 antiseptic Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 235000017709 saponins Nutrition 0.000 claims 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 30
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 abstract description 23
- 210000004556 brain Anatomy 0.000 abstract description 11
- 239000002207 metabolite Substances 0.000 abstract description 4
- 229930182494 ginsenoside Natural products 0.000 abstract description 3
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 229920001282 polysaccharide Polymers 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- 210000002348 5-ht neuron Anatomy 0.000 abstract description 2
- 244000197580 Poria cocos Species 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 241000208966 Polygala Species 0.000 abstract 1
- 229930182432 Polygalasaponin Natural products 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 16
- 230000001430 anti-depressive effect Effects 0.000 description 14
- 229960000890 hydrocortisone Drugs 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002858 neurotransmitter agent Substances 0.000 description 11
- 230000009182 swimming Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 8
- 230000002936 tranquilizing effect Effects 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 7
- 230000001914 calming effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003340 mental effect Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960003914 desipramine Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- VZRKWGPIZJDNHC-LUNVCWBOSA-N Polygalic acid Polymers CC1(C)CC[C@@]2(CCC3=C(CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2C1)C(O)=O VZRKWGPIZJDNHC-LUNVCWBOSA-N 0.000 description 2
- VZRKWGPIZJDNHC-UHFFFAOYSA-N Polygalic acid Natural products CC1(C)CCC2(CCC3=C(CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(O)=O)C2C1)C(O)=O VZRKWGPIZJDNHC-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
本发明涉及一种对抑郁、焦虑症状有显著治疗作用的中药组合物“心悦”。该药物制剂是由人参、茯苓、石菖蒲、远志按一定比例混合，或经提取活性部位(人参皂苷、茯苓多糖、石菖蒲中的挥发性成分、远志皂苷等)后的组合物，可制备成各种剂型。本品适用于各种原因导致的抑郁、焦虑症状，其机理在于本品能使机体NE、5－HT及其代谢产物5－HIAA的含量升高，激活大脑中5－HT神经元，降低抑郁血浆中皮质类固醇的含量。The invention relates to a traditional Chinese medicine composition "Xinyue" which has significant therapeutic effects on depression and anxiety symptoms. The pharmaceutical preparation is a mixture of ginseng, Poria cocos, Shichangpu and polygala in a certain proportion, or a composition after extracting active parts (ginsenosides, poria cocos polysaccharides, volatile components in Shichangpu, polygala saponins, etc.), and can be prepared into Various dosage forms. This product is suitable for depression and anxiety symptoms caused by various reasons. The mechanism is that this product can increase the content of NE, 5-HT and its metabolite 5-HIAA in the body, activate 5-HT neurons in the brain, and reduce depression. Corticosteroid levels in plasma.
Description
Technical field
The invention belongs to the field of Chinese medicines, mainly provide a kind of and have a tangible antidepressant effect Chinese medicine composition by what Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae were formed, and by Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae through extract, concentrate, refining each active constituents of medicine that obtains, promptly ginsenoside, pachyman, Rhizoma Acori Graminei volatile ingredient/involatile constituent, polygalic acid are or/and the compositions that polysaccharide is formed.Be specifically related to depression, the application of anxiety symptom and the application for preparing antidepressant, anxiety product thereof that they cause at the treatment a variety of causes.In its antidepressant effect and the depressed animal blood slurry of its reduction in concentration of cortisol, the rising brain content of NE, 5-HT and metabolite 5-HIAA thereof relevant.
Technical background
The investigation of WHO shows, the sickness rate of depression is classified the 5th up to 10% as in the world's 10 big diseases, the sickness rate of domestic depression is 5.8%, about 5～20% people can suffer from depression a certain period in life, and depression will be one of the most serious disease of the 21 century mankind.Existing antidepressant Western medicine mainly is: tricyclic antidepressants (TCAs), selectivity 5-HT reuptake inhibitor (SSRIs), oxidase inhibitor (MAOIs), the toxic and side effects of their equal various degrees, and shortcoming such as cost an arm and a leg.Thereby the new antidepressants of research and development have important theory and practical significance from Chinese medicine.
Theory of Chinese medical science is thought " The heart controls mental activities, excess of the heart is then liked, have a guilty conscience then sad ", and depressed and anxiety are all relevant with the mind, the motive, painstaking effort.Main Ingredients and Appearance in the Chinese medicine composition of our prescription therapeutic depression, anxiety neurosis " heart is pleased " is the more Chinese medicine (computer statistics analysis) of frequency of utilization in successive dynasties hundreds of compound recipes of calming the nerves, rational compatibility after ancient Chinese medicine long-term practice and modern expert are to pharmacodynamic study.Its prescription is followed the Therapeutic Principle of the traditional Chinese medical science about " emotional disorder " fully: " reinforcing the heart of nourishing blood, tranquilizing the mind, waking up the patient from unconsciousness by clearing away phlegm " and decide.The medicine that has benefiting qi and nourishing blood to calm the nerves in " heart please " side has heart-spleen boosting and the medicine of mind tranquilizing and the heart calming, and having eliminates the phlegm has one's ideas straightened out and the medicine of mind tranquilizing and the heart calming, happy hole is arranged and the medicine of mind tranquilizing and the heart calming, and this prescription has embodied Chinese medicine compound multi-level, many target spots of curing the disease, inherent relevant characteristics.
Summary of the invention
The present invention disclose first the compositions of Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae and active component combination thereof be used for the treatment of the doctor trained in Western medicine category based on depressed, the mental sickness of anxiety symptom and the feelings will disease of traditional Chinese medical science category.
Can be according to the preparation process of routine, excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent will be added after Radix Ginseng, Poria, Rhizoma Acori Graminei, the Radix Polygalae pulverizing medicinal materials, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae can be obtained each active constituents of medicine through extracting, concentrate, making with extra care, promptly ginsenoside, pachyman, Rhizoma Acori Graminei volatile ingredient/involatile constituent, polygalic acid are or/and polysaccharide is made above-mentioned any dosage form after forming compositions.
Below will the invention will be further described by concrete example
Antidepressant effect and the study on mechanism thereof of embodiment 1 " heart is pleased "
1 material and method
1.1 the animal Kunming mouse is male, body weight 18～22g.Providing by Military Medical Science Institute's Experimental Animal Center. each organizes mice all under the same conditions, freely drinks water, ingests, keeps natural light.
1.2 medicine Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae (3: 3: 2: 2) all available from PLA General Hospital Chinese medicine pharmacy, soak 30min after, decoct 30min, twice merging filtrate is condensed into every 1ml and contains the 1g crude drug, 4 ℃ of refrigerators are preserved.Positive drug DESIPRAMINE (SIGMA company, lot number: 200-373-1).The hydrocortisone test kit is provided by the East Asia immunity.Standard substance: norepinephrine (Norepinephrine, NE, Sigma company, lot number; 200-095-0); Dopamine (Dopamine, DA, Sigma company, lot number: 200-527-8) 5-hydroxy tryptamine (5-hydroxytryptamine, 5-HT, Sigma company, lot number: 153-98-0); 5-hydroxyindoleacetic acid (5-hydrooxyindole-3-aceticacid, 5-HIAA, Sigma company, lot number: 200-195-4) trisodium citrate; Perchloric acid (Beijing chemical reagent work, analytical pure); Methanol (Beijing chemical reagent work, chromatographically pure); Water is the experiment ultra-pure water.
13 instruments, 1050 type high performance liquid chromatographs (U.S. Hewlett-Packard); 1046 type fluorescence detectors (U.S. Hewlett-Packard); Bondapar Phenyl chromatographic column (U.S. waters company); The 15R refrigerated centrifuge (U.S. Heraeus biofuge) that exceeds the speed limit.
2 experimental techniques
2.1 the mandatory swimming test of mice
2.1.1 experiment grouping and administration: it is administration 1 day, 3 days, 5 days, 7 days, 14 days district's groups that mice is distinguished component at random, and each district's group is divided into matched group at random, positive controls, ' heart is pleased ' high, medium and low dosage group.Matched group is given and normal saline 0.2ml/20g, and positive controls is given and Desipramine 0.2mg/20g, and high, medium and low dosage group is given and crude drug 0.12ml/20g, 0.06ml/20g, 0.03ml/20g.Each group is irritated stomach, 1 time/day.
2.1.2 the mensuration of mice dead time: each district group mice carries out the forced swimming experiment behind the successive administration last.Mice is put into high 20cm, in the glass beaker of diameter 10cm, the dark 10cm of water in the cup, water temperature 25 ℃ ± 1,1 in each beaker begins behind the 2min to observe, and observes to continue 4min, mice dead time (stop to struggle or apparent floating state, the persistent period of tiny limb motion to keep head to keep afloat only arranged) in water in this 4min of accumulative total.
2.2 hydrocortisone assay: mice after the swimming is extractd eyeball and gets blood, (5000rmin-1) centrifugal 5min at a high speed, and separation of serum is put-70 ℃ of refrigerators and is preserved to be measured.Adopt radio immunoassay (RIA) to measure hydrocortisone content, the operating procedure by specification carries out [2].
2.3 the mensuration of central neurotransmitter
Collection of specimens and processing: each district group mice carries out the forced swimming experiment behind the successive administration last, sacrificed by decapitation mice after swimming finishes, head is placed on the ice platform, rapidly brain is taken out, place liquid nitrogen container, after leave in-78 ℃ of cryogenic refrigerators, treat that whole sample collections fully after, carry out the mensuration of neurotransmitter.Test was taken out cerebral tissue and add the ice-cold 0.1mol/L HCLO4 of 0.5ml the same day, operates in ice bath with glass homogenizer, and 4 ℃, the centrifugal 30min of 15000g, the taking-up supernatant, recentrifuge 10min gets supernatant, direct injected 50 μ l.
Chromatographic condition: mobile phase is the 20mmol/L trisodium citrate, and regulating PH with Hcl is 5.0, adds the methanol of 5% (V/V) behind the membrane filtration of 0.45 μ m, and through ultrasonic degas, flow velocity is 1.0ml/min before using.The fluorescence detector wavelength is set to: excitation wavelength (EM) 280nm, emission wavelength (EX) 315nm; With peak area quantification.
The preparation of standard substance and the preparation of standard curve: precision takes by weighing NE, DA, 5-HT, 5-HIAA, places the 10ml volumetric flask respectively, adds 0.1mol/lHCLO
4To scale, shake up.Get NE131ug/ml, DA 127 μ g/ml, 5-HT 111 μ g/ml, 5-HIAA 107 μ g/ml standard solution respectively.Get above-mentioned standard solution and get NE, DA, 5-HT, 5-HIAA series concentration respectively through dilution preparation standard curve.Area under curve behind the sample introduction (Y) returns concentration (X).
2.4 the statistical method experimental result is used the SPSS statistical software, adopts variance analysis, group difference carries out with the T check, and gained is the result represent with x ± S.
3. result
3.1 ' heart is pleased ' is to the influence of the mandatory swimming of mice
Table 1 " heart please " is to the influence of the mandatory swimming of mice (X ± S)
The mandatory non-swimming time of mice (s)
Group n 1 day 3 days 5 days 7 days 14 days
High dose group 10 57.7 ± 21.9
*94.5 ± 17.7 72.8 ± 22.4 62.6 ± 21.1
*102.7 ± 35.7
Middle dosage group 10 38.0 ± 28.9
*69.4 ± 24.4
*58.4 ± 29.4
*57.5 ± 29.5
*74.3 ± 12.1
*
Low dose group 10 87.9 ± 12.9
*97.0 ± 31.8 96.9 ± 19.3 67.0 ± 19.8
*112.3 ± 22.9
Positive drug group 10 29.3 ± 9.7
*44.7 ± 20.6
*58.0 ± 22.6
*55.0 ± 23.3
*48.7 ± 23.0
*
Matched group 10 94.6 ± 18.6 108.7 ± 24.3 114.8 ± 27.9 139.9 ± 28.5 132.3 ± 13.0
*Compare P＜0.05 with matched group
*Compare P＜0.01 with matched group
3.2 " heart is pleased " is to the influence of mice plasma hydrocortisone
Table 2 " heart please " is to the influence of mice plasma hydrocortisone content (X ± S)
N hydrocortisone content (ng/ml)
1 day 3 days 5 days 7 days 14 days
Normal group 10 15.8 ± 2.4 13.9 ± 3.3 16.4 ± 6.5 13.6 ± 4.1 14.9 ± 5.7
Matched group 10 69.3 ± 9.2
##56.6 ± 15.1
##61.4 ± 5.3
##53.7 ± 7.4
##58.4 ± 17.7
##
Positive controls 10 44.9 ± 5.2
##53.3 ± 5.3
##56.6 ± 9.7
##54.1 ± 5.7
##49.7 ± 9.1
##
High dose group 10 54.3 ± 8.0
##56.3 ± 6.7
##47.0 ± 7.6
* ##32.2 ± 8.1
* ##47.3 ± 6.2
##
Middle dosage group 10 46.9 ± 3.1
* ##48.5 ± 9.4
##50.1 ± 2.9
##29.8 ± 6.3
* ##30.3 ± 6.7
* ##
Low dose group 10 41.3 ± 2.0
* ##56.5 ± 5.2
##61.8 ± 7.7
##52.5 ± 12.8
##53.3 ± 9.0
##
*Compare P＜0.05 with matched group
##Compare P＜0.01 with normal group
3.2 " heart is pleased " is to the influence of neurotransmitter in the mouse brain
Table 3 " heart is pleased " different dosing time depression model mice central neurotransmitter NE content (μ g/g wet tissue)
Administration administration in 1 day administration in 3 days administration in 5 days administration in 7 days 14 days
Negative control group (n=6) 0.69 ± 0.03 0.76 ± 0.03 0.91 ± 0.01 0.51 ± 0.07 0.82 ± 0.06
Positive controls (n=6) 0.70 ± 0.06 1.10 ± 0.01
*1.35 ± 0.01
*1.25 ± 0.02
*1.25 ± 0.01
*
High dose group (n=6) 0.70 ± 0.03 0.74 ± 0.03 1.06 ± 0.02
*0.68 ± 0.08 0.88 ± 0.06
Middle dosage group (n=6) 0.71 ± 0.05 0.95 ± 0.06
*0.94 ± 0.13 0.68 ± 0.05 0.89 ± 0.02
Low dose group (n=6) 0.77 ± 0.01 0.90 ± 0.13 1.09 ± 0.02
*0.83 ± 0.13
*0.86 ± 0.19
Table 4 " heart is pleased " different dosing time depression model mice central neurotransmitter DA content (μ g/g wet tissue)
Administration administration in 1 day administration in 3 days administration in 5 days administration in 7 days 14 days
Negative control group (n=6) 0.96 ± 0.01 0.98 ± 0.14 1.05 ± 0.07 0.84 ± 0.13 1.10 ± 0.05
Positive controls (n=6) 0.95 ± 0.06 0.94 ± 0.01 1.09 ± 0.01 0.96 ± 0.02 1.06 ± 0.01
High dose group (n=6) 1.00 ± 0.07 0.93 ± 0.01 1.30 ± 0.11 0.98 ± 0.11 1.10 ± 0.03
Middle dosage group (n=6) 1.49 ± 0.68 1.17 ± 0.17 1.14 ± 0.03 0.93 ± 0.01 1.09 ± 0.10
Low dose group (n=6) 0.95 ± 0.06 1.39 ± 0.41 1.23 ± 0.01 1.02 ± 0.06 1.03 ± 0.22
Table 5 " heart is pleased " different dosing time depression model mice central neurotransmitter 5-HT content (μ g/g wet tissue)
Administration administration in 1 day administration in 3 days administration in 5 days administration in 7 days 14 days
Negative control group (n=6) 1.43 ± 0.05 3.49 ± 0.45 3.07 ± 0.11 1.29 ± 0.15 1.41 ± 0.04
Positive controls (n=6) 1.73 ± 0.07
*1.82 ± 0.01
*1.65 ± 0.01
*1.92 ± 0.02
*1.85 ± 0.01
*
High dose group (n=6) 1.53 ± 0.08 3.22 ± 0.06
*3.35 ± 0.36 1.74 ± 0.03
*1.72 ± 0.06
*
Middle dosage group (n=6) 1.47 ± 0.07 3.51 ± 0.41 2.73 ± 0.31 1.50 ± 0.10
*1.58 ± 0.01
*
Low dose group (n=6) 1.36 ± 0.01 3.82 ± 0.43 2.98 ± 0.18 1.74 ± 0.24
*1.51 ± 0.07
Table 6 " heart is pleased " different dosing time depression model mice central neurotransmitter 5-HIAA content (μ g/g wet tissue)
Administration administration in 1 day administration in 3 days administration in 5 days administration 14 in 7 days is big
Negative control group (n=6) 0.16 ± 0.06 0.28 ± 0.12 0.26 ± 0.05 0.39 ± 0.08 0.32 ± 0.01
Positive controls (n=6) 0.11 ± 0.01 0.30 ± 0.01 0.24 ± 0.01 0.28 ± 0.02 0.35 ± 0.01
High dose group (n=6) 0.11 ± 0.01 0.39 ± 0.01 0.44 ± 0.08
*0.40 ± 0.01 0.38 ± 0.06
Middle dosage group (n=6) 0.21 ± 0.16 0.53 ± 0.12
*0.34 ± 0.01
*0.40 ± 0.01 0.42 ± 0.02
*
Low dose group (n=6) 0.28 ± 0.06
*0.49 ± 0.06
*0.51 ± 0.01
*0.56 ± 0.04* 0.53 ± 0.04
*
Table 7 " heart is pleased " different dosing time depression model mice central neurotransmitter 5-HT/5-HIAA ratio
Administration administration in 1 day administration in 3 days administration in 5 days administration in 7 days 14 days
Negative control group (n=6) 8.94 ± 0.08 12.46 ± 0.38 11.80 ± 0.94 3.31 ± 0.65 4.41 ± 0.96
Positive controls (n=6) 15.72 ± 0.14 6.06 ± 0.77 6.88 ± 0.28 6.85 ± 0.34 5.29 ± 0.14
High dose group (n=6) 13.9 ± 0.56
*8.26 ± 0.41
*7.61 ± 0.09
*4.35 ± 0.52 4.53 ± 0.37
Middle dosage group (n=6) 7 ± 0.19
*6.62 ± 0.67
*8.03 ± 0.35
*3.75 ± 0.18 3.76 ± 0.71
Low dose group (n=6) 4.86 ± 0.21
*7.8 ± 0.34
*5.84 ± 0.24
*3.1 ± 0.45 2.85 ± 0.65
4. conclusion
A kind of stable, reliable, classical depression model---forced swimming model is adopted in this experiment, the antidepressant effect of having investigated " heart is pleased " carries out Study on mechanism simultaneously, measures " heart is pleased " influence to monoamine neurotransmitter content in depression model mice plasma hydrocortisone content and the brain.The result shows that " heart is pleased " each dosage group all can shorten the dead time during the mandatory swimming of mice in various degree, has compared significant statistical significance with matched group.Prompting " heart is pleased " is similar to clinical antidepressant Western medicine desipramine (positive control drug) effect, the effect with tangible antidepressant and anxiety, but desipramine has significant side effects, and " heart is pleased " is without any side effects.
It is generally acknowledged, the content of depressed generation and the interior neurotransmitter of brain such as dopamine, 5-hydroxy tryptamine, norepinephrine is relevant, present studies show that, the cerebrospinal fluid of depressive patients, blood plasma and urocortisol raise, can not suppress hydrocortisone (7) in the blood with dexamethasone, the prompting depression also raises with hydrocortisone substantial connection." heart is pleased " influence to monoamine neurotransmitter content in depression model mice plasma hydrocortisone content and the brain has been measured in this research, the result shows, " heart is pleased " can reduce hydrocortisone content in the depressed animal blood slurry, the content of mouse brain interior NE, 5-HT and metabolite 5-HIAA thereof is raise, and the ratio of 5-HT/5-HIAA is on a declining curve, and prompting " heart is pleased " has activation to 5-HT neuron in the mouse brain.
In sum, our Chinese medicine of being made up of Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae that studies show that has tangible antidepressant effect, in its antidepressant effect and the depressed animal blood slurry of its reduction in concentration of cortisol, the rising brain content of NE, 5-HT and metabolite 5-HIAA thereof relevant.
Embodiment 2 hearts are pleased the depressed clinical impression of treatment and are observed
1, diagnostic criteria
Object is from the Neurology Department psychology consultation clinic, and we adopt Zung self-appraisal depression scale (SDS) and self-appraisal depressive symptom self-appraisal scale (Wakefield table), and evaluation once before administration.Secondary cases depression person due to the eliminating physical disease is as the object of observation.The same evaluation table of reuse is evaluated once after the administration, and clinical efficacy is by 4 grades of evaluations.
The patient has 16 examples, male's 11 examples, and women's 5 examples, 21～52 years old age, the people of schooling junior middle schools 4,3 people of senior middle school, above 9 people of junior college do blood, routine urinalysis, liver, renal function and Electrocardioscopy before the treatment.
2, method:
After seeking advice from, patient promptly stops using other antidepressant drug 7 days, take " heart is pleased " water decoction (Radix Ginseng 1-9g, Poria 3-12g, stone Chang 1-6g, Radix Polygalae 0.5-2g) then, 1 dose of decoction day takes 2 times, take medicine and carry out Zung self-appraisal depression scale (SDS) and Self-Rating Anxiety Scale (SAS) scoring after 4 weeks, and do blood, routine urinalysis, liver, renal function and Electrocardioscopy.
3, therapeutic outcome
Recovery from illness: mental symptom all disappears, and emotion is optimistic, and insight recovers; Produce effects: mental symptom disappears substantially, and insight is most of to be recovered; Effectively: mental symptom is improved substantially, and insight partly recovers; Invalid: mental symptom does not have improvement.Among the 16 routine patients, 11 examples of fully recovering, produce effects 3 examples, effective 1 example, invalid 1 example; Obvious effective rate 87.5%, effective percentage 93.8%.
The scale scoring:
SDS scoring: be 45.92 ± 3.9 before the treatment; Treatment back 35.43 ± 9.33, the scoring of treatment back significantly descends; Wakefield shows scoring: being 23.68 ± 5.72 before the treatment, is 13.55 ± 3.95 after the treatment, and the scoring of treatment back significantly descends.
Untoward reaction
After taking medicine, the patient do not see obvious adverse reaction.
Model case:
The patient * * *, man, 20 years old, the sophomore, during senior middle school and the classmate quarrel and fight noisily after head collided, headache, giddy appear, nervous, insomnia, suspect own head angiorrhexis, occur anorexia, depressed, school grade decline then, row Zung self-appraisal depression scale (SDS) scoring 45 minutes, nervous system and the internal medicine no abnormality seen of having a medical check-up, every inspections such as Cranial Computed Tomography inspection, electrocardio, brain electricity are all normal, got rid of organic disease, and clinical diagnosis is a depression.Take " heart please " water decoction, take 2 times 1 dose of decoction day, take medicine 4 week the back above-mentioned symptoms obviously alleviate, carrying out Zung self-appraisal depression scale (SDS) scoring is 23 minutes, depressive symptom is obviously alleviated, and carries out blood, routine urinalysis, liver, renal function and Electrocardioscopy no abnormality seen.
4, discuss
At present, clinically had multiple effective antidepressant, still, still had 1/3 patient effect very undesirable approximately, and it is obvious to take toxic and side effects for a long time.For example, effective although desipramine is treated depression clinically, tangible asthenia also appears, calm and cholinolytic activity side effect such as (causing xerostomia, forgetful).Therefore, seek antidepressant imperative novel, low toxicity.Based on Chinese medicine compound clinical experience in thousand and its homogeneity of curing the disease and globality, Chinese medicine compound may have unique antidepressant effect.
Theory of Chinese medical science is thought " The heart controls mental activities, excess of the heart is then liked, have a guilty conscience then sad ", and depressed and anxiety are all relevant with the mind, the motive, painstaking effort." heart please " prescription is followed the Therapeutic Principle of the traditional Chinese medical science about " emotional disorder " fully: " reinforcing the heart of nourishing blood, tranquilizing the mind, waking up the patient from unconsciousness by clearing away phlegm " and decide.The medicine that has benefiting qi and nourishing blood to calm the nerves in " heart please " side has heart-spleen boosting and the medicine of mind tranquilizing and the heart calming, and having eliminates the phlegm has one's ideas straightened out and the medicine of mind tranquilizing and the heart calming, happy hole is arranged and the medicine of mind tranquilizing and the heart calming, and this prescription has embodied Chinese medicine compound multi-level, many target spots of curing the disease, inherent relevant characteristics.
This clinical experiment adopts Zung self-appraisal depression scale to investigate the antidepressant effect of " heart is pleased ".The result shows that depression, anxiety symptom that " heart is pleased " causes for a variety of causes have obvious effects, and without any side effects.
Claims (4)
1. one kind to the Chinese medicine composition depressed, that anxiety symptom has remarkable therapeutical effect " heart is pleased ", it is characterized in that being made by the raw material of following parts by weight: (ratio is 3: 3: 2: 2 or 3: 5: 6: 2) for Radix Ginseng, Poria, Rhizoma Acori Graminei, Radix Polygalae.
2. Chinese medicine composition according to claim 1 comprises the compositions " heart is pleased " that the chemical analysis such as saponin in volatile oil, alkaloid and the Radix Polygalae in Radix Ginseng total saponins (comprising each monomer saponin), pachyman, the Rhizoma Acori Graminei are formed.
3. according to claim 1 and the described Chinese medicine composition of claim 2, be meant excipient substances such as adding conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
4. application according to claim 1, wherein the depression of indication, anxiety symptom are meant because anxiety, the depressive symptom (the strongly fragrant disease of the feelings will disease traditional Chinese medical science that comprises traditional Chinese medical science category) that a variety of causes causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02148620 CN1241599C (en) | 2002-11-13 | 2002-11-13 | Traditional Chinese medicine composition for blahs and anxiety |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02148620 CN1241599C (en) | 2002-11-13 | 2002-11-13 | Traditional Chinese medicine composition for blahs and anxiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1500509A true CN1500509A (en) | 2004-06-02 |
| CN1241599C CN1241599C (en) | 2006-02-15 |
Family
ID=34233225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02148620 Expired - Fee Related CN1241599C (en) | 2002-11-13 | 2002-11-13 | Traditional Chinese medicine composition for blahs and anxiety |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1241599C (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387293C (en) * | 2005-04-22 | 2008-05-14 | 高学敏 | Medicine composition and preparing method |
| CN102119986A (en) * | 2011-03-07 | 2011-07-13 | 北京中医药大学 | Traditional Chinese medicine extract with anti-dementia effect and preparation method thereof |
| CN102188466A (en) * | 2011-04-15 | 2011-09-21 | 电子科技大学 | Novel anti-depression compound preparation |
| CN103609936A (en) * | 2013-11-18 | 2014-03-05 | 无限极（中国）有限公司 | Application of acorus gramineus polysaccharide in preparing healthcare food having neuroprotective effect |
| CN105192195A (en) * | 2014-11-27 | 2015-12-30 | 青岛申达高新技术开发有限公司 | Anti-fatigue eleutherococcus senticosus health tea and preparation method thereof |
| CN105412843A (en) * | 2015-12-30 | 2016-03-23 | 南京中医药大学 | Traditional Chinese medicine composition capable of enhancing memory and relieving depression, preparation method and applications thereof |
| CN105664044A (en) * | 2016-03-03 | 2016-06-15 | 吉林省通化博祥药业股份有限公司 | Traditional Chinese medicine combined extract with anti-depression effect as well as preparation method and application thereof |
| CN105663506A (en) * | 2016-03-01 | 2016-06-15 | 南京中医药大学 | Traditional Chinese medicine extract with anti-depression effect and application thereof |
| CN107737207A (en) * | 2017-11-30 | 2018-02-27 | 山西中医药大学 | Pharmaceutical composition with antidepressant effect and its production and use |
| CN109820932A (en) * | 2019-01-25 | 2019-05-31 | 沈阳药科大学 | A traditional Chinese medicine standard decoction for preventing and treating senile dementia |
| CN110623969A (en) * | 2019-09-05 | 2019-12-31 | 河北中医学院 | A composition formula for treating amnesia |
| CN112336796A (en) * | 2019-08-06 | 2021-02-09 | 中国科学院烟台海岸带研究所 | Pharmaceutical composition with effects of relieving anxiety and improving depression and application thereof |
| CN116688037A (en) * | 2023-07-19 | 2023-09-05 | 中国人民解放军总医院 | Preparation method and application of pistachio-capsule powder active component |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168024B (en) * | 2007-10-25 | 2010-12-01 | 北京星昊医药股份有限公司 | Proprietary Chinese medicine for treating depression and production method thereof |
-
2002
- 2002-11-13 CN CN 02148620 patent/CN1241599C/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387293C (en) * | 2005-04-22 | 2008-05-14 | 高学敏 | Medicine composition and preparing method |
| CN102119986A (en) * | 2011-03-07 | 2011-07-13 | 北京中医药大学 | Traditional Chinese medicine extract with anti-dementia effect and preparation method thereof |
| CN102119986B (en) * | 2011-03-07 | 2013-03-27 | 北京中医药大学 | Traditional Chinese medicine extract with anti-dementia effect and preparation method thereof |
| CN102188466A (en) * | 2011-04-15 | 2011-09-21 | 电子科技大学 | Novel anti-depression compound preparation |
| CN103609936A (en) * | 2013-11-18 | 2014-03-05 | 无限极（中国）有限公司 | Application of acorus gramineus polysaccharide in preparing healthcare food having neuroprotective effect |
| CN103609936B (en) * | 2013-11-18 | 2015-12-30 | 无限极（中国）有限公司 | Grass-leaved sweetflag polysaccharide is preparing the application had in the health food of neuroprotection |
| CN105192195A (en) * | 2014-11-27 | 2015-12-30 | 青岛申达高新技术开发有限公司 | Anti-fatigue eleutherococcus senticosus health tea and preparation method thereof |
| CN105412843B (en) * | 2015-12-30 | 2019-07-16 | 南京中医药大学 | Traditional Chinese medicine composition with the effects of enhancing memory and improving depression and its preparation method and application |
| CN105412843A (en) * | 2015-12-30 | 2016-03-23 | 南京中医药大学 | Traditional Chinese medicine composition capable of enhancing memory and relieving depression, preparation method and applications thereof |
| CN105663506A (en) * | 2016-03-01 | 2016-06-15 | 南京中医药大学 | Traditional Chinese medicine extract with anti-depression effect and application thereof |
| CN105664044A (en) * | 2016-03-03 | 2016-06-15 | 吉林省通化博祥药业股份有限公司 | Traditional Chinese medicine combined extract with anti-depression effect as well as preparation method and application thereof |
| CN107737207A (en) * | 2017-11-30 | 2018-02-27 | 山西中医药大学 | Pharmaceutical composition with antidepressant effect and its production and use |
| CN107737207B (en) * | 2017-11-30 | 2020-09-11 | 山西中医药大学 | Pharmaceutical composition with antidepressant effect and preparation method and application thereof |
| CN109820932A (en) * | 2019-01-25 | 2019-05-31 | 沈阳药科大学 | A traditional Chinese medicine standard decoction for preventing and treating senile dementia |
| CN112336796A (en) * | 2019-08-06 | 2021-02-09 | 中国科学院烟台海岸带研究所 | Pharmaceutical composition with effects of relieving anxiety and improving depression and application thereof |
| CN110623969A (en) * | 2019-09-05 | 2019-12-31 | 河北中医学院 | A composition formula for treating amnesia |
| CN116688037A (en) * | 2023-07-19 | 2023-09-05 | 中国人民解放军总医院 | Preparation method and application of pistachio-capsule powder active component |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1241599C (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1500509A (en) | A kind of traditional Chinese medicine composition for treating depression and anxiety | |
| CN1965966A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN101337034B (en) | Oral traditional Chinese preparation for treating craniocerebral injury syndrome and preparation method thereof | |
| CN100349568C (en) | Intravenous administered injection of ginkgolide B, its preparation method and application | |
| Taiwo et al. | Cardiovascular effects of Vernonia amygdalina in rats and the implications for treatment of hypertension in diabetes | |
| CN106880701B (en) | A kind of preparation method of compound Osteitis Babu Tie traditional Chinese medicine extract | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1415303A (en) | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia | |
| CN1241611C (en) | Medicine for treating hypertension and its preparing process | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| CN102988505B (en) | Medicine composition for treating erectile dysfunction and preparation method thereof | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1640484A (en) | Chinese medicine soft capsule Naodesheng and its preparing method | |
| CN1919240A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN108567753A (en) | All beam dripping pill and its preparation process | |
| CN1582946A (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1233359C (en) | Compound Jigucao capsule (Abrus fruticulosus Wall. ex Wight et Arn.) and its prodn. method | |
| CN1704113A (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN1663599A (en) | Improved plaster for treating rheumatic and rheumatoid diseases and preparation method thereof | |
| CN1596960A (en) | Traditional Chinese medicine for treating brain arteria induration | |
| CN1919239A (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1872165A (en) | A medicine combination, preparation method and method for controlling quality | |
| CN1919252A (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1328839A (en) | Medicine for reducing blood pressure and cleaning fat and its production method | |
| CN1305493C (en) | Chinese medicine effective part for treating cerebral apoplexy and its separation preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060215 Termination date: 20171113 |